The Investigation of Hsp90C-Terminal Inhibitors Containing Amide Bioisosteres

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Heat Shock Protein 90 (Hsp90) is crucial for the stability and function of numerous client proteins, many of which are implicated in cancer development.
• Hsp90's role in multiple oncogenic pathways makes it a promising therapeutic target, particularly in melanoma.
• Inhibiting Hsp90 can simultaneously disrupt several cancer-promoting pathways, offering a potential strategy for effective treatment.

Purpose of the Study:

• To synthesize and evaluate a series of novel Hsp90 C-terminal inhibitors.
• To assess the anti-proliferative activity of these inhibitors against melanoma cell lines with varying BRAF mutation statuses.
• To explore the structure-activity relationships (SAR) of a lead compound, focusing on modifications to the amide moiety.

Main Methods:

• Synthesis of a novel series of Hsp90 C-terminal inhibitors.
• Evaluation of anti-proliferative activity using IC50 assays against melanoma cell lines (SKMel173, SKMel103, SKMel19, A375).
• Structure-activity relationship studies involving the introduction of amide bioisosteres into a lead inhibitor (Compound 6).

Main Results:

• The synthesized Hsp90 C-terminal inhibitors demonstrated significant anti-proliferative effects on melanoma cells.
• Compound 6 exhibited potent activity with IC50 values ranging from 0.607 μM to 1.413 μM across different cell lines.
• SAR studies provided insights into optimizing the inhibitor structure for enhanced efficacy.

Conclusions:

• Novel Hsp90 C-terminal inhibitors possess significant anti-proliferative activity against melanoma cells.
• The developed compounds, particularly Compound 6, represent promising candidates for further investigation in melanoma therapy.
• Targeting Hsp90 offers a viable strategy for simultaneously disrupting multiple oncogenic pathways in cancer treatment.